1-Bromooctane → 5-(2,3-Difluoro-4-octyloxyphenyl)-2-(6-hexyloxypyridin-3-yl)pyrimidine
反応式
[F:1][C:2]1[C:7]([F:8])=[C:6]([OH:9])[CH:5]=[CH:4][C:3]=1[C:10]1[CH:11]=[N:12][C:13]([C:16]2[CH:17]=[N:18][C:19]([O:22][CH2:23][CH2:24][CH2:25][CH2:26][CH2:27][CH3:28])=[CH:20][CH:21]=2)=[N:14][CH:15]=1.Br[CH2:30][CH2:31][CH2:32][CH2:33][CH2:34][CH2:35][CH2:36][CH3:37]>CN(C=O)C>[F:1][C:2]1[C:7]([F:8])=[C:6]([O:9][CH2:30][CH2:31][CH2:32][CH2:33][CH2:34][CH2:35][CH2:36][CH3:37])[CH:5]=[CH:4][C:3]=1[C:10]1[CH:15]=[N:14][C:13]([C:16]2[CH:17]=[N:18][C:19]([O:22][CH2:23][CH2:24][CH2:25][CH2:26][CH2:27][CH3:28])=[CH:20][CH:21]=2)=[N:12][CH:11]=1参加物
4
実験手順
The etherification of 12 mmol of 5-(2,3-difluoro-4-hydroxyphenyl)-2-(6-hexyloxypyridin-3-yl)pyrimidine using 13.2 mmol of 1-bromooctane in 100 ml of DMF is carried out analogously to the procedure indicated for Example 3. The crude product is chromatographed on silica gel 60 using dichloromethane as eluent and is recrystallized from n-heptane and toluene, giving 3.6 g (61%) of colorless crystals, whose analytical data correspond to those of the compound obtained as described in 1a).